Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPHE: Lanreotide Autogel Administration Preference in NETs
NCT00681187Phase 4Completed
- Sponsor
- Ipsen
- Start
- Jun 2008
- Primary completion
- Aug 2010
- Modality
- Peptides
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of lanreotide in Neuroendocrine Neoplasm (NEN) (2 arms), sponsored by Ipsen. Primary endpoint: Subject Preference for Self or Partner Administration. Started Jun 2008; status: completed.
02
Drugs
lanreotide
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00681187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00681187.